AR072578A1 - Compuestos de piperidina puenteada tipo quinoxalina sustituida y los usos de los mismos - Google Patents

Compuestos de piperidina puenteada tipo quinoxalina sustituida y los usos de los mismos

Info

Publication number
AR072578A1
AR072578A1 ARP090102759A AR072578A1 AR 072578 A1 AR072578 A1 AR 072578A1 AR P090102759 A ARP090102759 A AR P090102759A AR 072578 A1 AR072578 A1 AR 072578A1
Authority
AR
Argentina
Prior art keywords
independently selected
piperidine
same
quinoxaline
replaced type
Prior art date
Application number
Other languages
English (en)
Original Assignee
Purdue Pharma Lp
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41077776&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR072578(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Purdue Pharma Lp, Shionogi & Co filed Critical Purdue Pharma Lp
Publication of AR072578A1 publication Critical patent/AR072578A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Composiciones que comprenden una cantidad efectiva de un compuesto de piperidina puenteada tipo quinoxalina sustituida y métodos para tratar o prevenir una condicion, tales como dolor, que comprende administrar a un animal que lo necesita una cantidad efectiva de un compuesto de piperidina puenteada tipo quinoxalina sustituida. Reivindicacion 1: Un compuesto caracterizado porque tiene la formula (1) o un derivado farmacéuticamente aceptable de lo mismo, de donde cada R2 es independientemente seleccionado de -halogeno; a es un numero entero seleccionado de 0, 1 o 2; b es un numero entero seleccionado de 0 o 1; cada R5 es independientemente seleccionado de -H, -OH, -alquilo C1-3, -C(halo)3, o -halogeno; R1 es -cicloalquilo C9-14 o -bicicloalquilo C9-14, cada una de los cuales está sustituido con 1, 2 o 3 grupos R3 independientemente seleccionados; cada R3 es independientemente seleccionado de alquilo C1-4, -alquenilo C2-6, alquinilo C2-6, o cicloaIquil C3-6.
ARP090102759 2008-07-21 2009-07-20 Compuestos de piperidina puenteada tipo quinoxalina sustituida y los usos de los mismos AR072578A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8248208P 2008-07-21 2008-07-21

Publications (1)

Publication Number Publication Date
AR072578A1 true AR072578A1 (es) 2010-09-08

Family

ID=41077776

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090102759 AR072578A1 (es) 2008-07-21 2009-07-20 Compuestos de piperidina puenteada tipo quinoxalina sustituida y los usos de los mismos

Country Status (32)

Country Link
US (6) US8476271B2 (es)
EP (2) EP2537844A1 (es)
JP (1) JP5416210B2 (es)
KR (1) KR101333660B1 (es)
CN (1) CN102105465B (es)
AR (1) AR072578A1 (es)
AU (1) AU2009275218C1 (es)
BR (1) BRPI0911031B8 (es)
CA (1) CA2730288C (es)
CL (1) CL2011000148A1 (es)
CO (1) CO6341627A2 (es)
CY (1) CY1113485T1 (es)
DK (1) DK2324013T6 (es)
ES (1) ES2393849T7 (es)
HK (1) HK1157763A1 (es)
HR (1) HRP20120841T4 (es)
IL (2) IL210549A (es)
MX (1) MX2011000872A (es)
MY (1) MY153948A (es)
NZ (1) NZ590416A (es)
PE (2) PE20140102A1 (es)
PL (1) PL2324013T6 (es)
PT (1) PT2324013E (es)
RS (1) RS52590B2 (es)
RU (1) RU2500678C2 (es)
SG (1) SG192539A1 (es)
SI (1) SI2324013T1 (es)
SM (1) SMT201200053B (es)
TW (2) TW201016697A (es)
UA (1) UA99540C2 (es)
WO (1) WO2010010458A1 (es)
ZA (1) ZA201100189B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090176796A1 (en) 2007-04-27 2009-07-09 Purdue Pharma L. P. Trpv1 antagonists including amide substituent and uses thereof
MX2010002449A (es) 2007-08-31 2010-09-07 Purdue Pharma Lp Compuestos de piperidina tipo quinoxalina sustituida y uso de los mismsos.
WO2010010458A1 (en) 2008-07-21 2010-01-28 Purdue Pharma L.P. Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof
EP2654751B1 (en) * 2010-12-22 2016-11-23 Purdue Pharma L.P. Phosphorus-substituted quinoxaline-type piperidine compounds and uses thereof
PE20141531A1 (es) 2011-06-22 2014-10-23 Purdue Pharma Lp Antagonistas de trpv1 que incluyen sustituyentes dihidroxi y sus usos
AU2012293417A1 (en) 2011-08-10 2013-05-02 Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof
AU2012324015A1 (en) * 2011-12-01 2013-06-20 Purdue Pharma L.P. Azetidine-substituted quinoxaline-type piperidine compounds and uses thererof
US9085561B2 (en) 2012-07-30 2015-07-21 Purdue Pharma L.P. Cyclic urea- or lactam-substituted quinoxaline-type piperidines as ORL-1 modulators
US9090618B2 (en) 2012-12-27 2015-07-28 Purdue Pharma L.P. Substituted benzimidazole-type piperidine compounds and uses thereof
US10118927B2 (en) 2012-12-27 2018-11-06 Purdue Pharma L.P. Substituted piperidin-4-amino-type compounds and uses thereof
WO2014102592A2 (en) 2012-12-27 2014-07-03 Purdue Pharma L.P. Oxime/substituted quinoxaline-type piperidine compounds and uses thereof
US9963458B2 (en) 2012-12-27 2018-05-08 Purdue Pharma L.P. Indole and indoline-type piperidine compounds and uses thereof
JOP20190008A1 (ar) * 2016-07-26 2019-01-24 Purdue Pharma Lp علاج ومنع اضطرابات النوم
AU2019212435B2 (en) * 2018-01-24 2022-03-10 Purdue Pharma L. P. Sleep disorder treatment and prevention
AU2020213989B2 (en) * 2019-01-31 2023-06-15 Purdue Pharma L.P. Polymorphic forms of a substituted-quinoxaline-type bridged-piperidine compound
BR112023023702A2 (pt) * 2021-05-21 2024-01-30 Purdue Pharma Lp Métodos de tratamento da cistite intersticial/síndrome da dor na bexiga
WO2023250190A1 (en) * 2022-06-24 2023-12-28 Purdue Pharma L.P. Methods of treating or preventing overactive bladder syndrome

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5225402A (en) * 1989-02-10 1993-07-06 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US20020061554A1 (en) * 1992-08-13 2002-05-23 Evans Christopher J. Orphan opioid receptor and recombinant materials for its production
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
ATE216580T1 (de) 1993-07-16 2002-05-15 Merck & Co Inc Benzoxazinon- und benzopyrimidinon- piperidinyl- verbindungen als tokolytische oxytocin-rezeptor- antagonisten
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
WO1996041626A1 (en) 1995-06-12 1996-12-27 G.D. Searle & Co. Compositions comprising a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
JP3776201B2 (ja) 1997-04-17 2006-05-17 株式会社リコー 光記録媒体
JP4366532B2 (ja) 1997-05-30 2009-11-18 萬有製薬株式会社 ２−オキソイミダゾール誘導体
US6348461B1 (en) 1997-09-01 2002-02-19 Kyorin Pharmaceutical Co., Ltd. 6,7-asymmetrically disubstituted quinoxalinecarboxylic acid derivatives, addition salts thereof, and processes for the preparation of both
SE9800836D0 (sv) 1998-03-13 1998-03-13 Astra Ab New Compounds
JP2002509923A (ja) 1998-03-31 2002-04-02 ワーナー−ランバート・カンパニー Ｘａ因子およびトロンビンのようなセリンプロテアーゼ阻害剤としてのキノキサリノン
ATE496035T1 (de) * 1998-03-31 2011-02-15 Kyowa Hakko Kirin Co Ltd Stickstoffenthaltende heterocyclische verbindungen
US6262066B1 (en) 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
ID29137A (id) * 1998-07-27 2001-08-02 Schering Corp Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1
MA26659A1 (fr) 1998-08-06 2004-12-20 Pfizer Dérivés de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procédé pour leur préparation.
DE60033071T2 (de) 1999-12-06 2007-08-23 Euro-Celtique S.A. Triazospiroverbindungen mit nociceptin-rezeptoraffinität
WO2001039775A1 (en) 1999-12-06 2001-06-07 Euro-Celtique, S.A. Benzimidazole compounds having nociceptin receptor affinity
WO2001090102A2 (de) 2000-05-24 2001-11-29 Bayer Aktiengesellschaft 6-heterocyclyl-3-oxo-3,4-dihydro-chinoxaline
JP4380992B2 (ja) 2001-04-18 2009-12-09 ユーロ−セルティーク エス．エイ． ノシセプチン類似体
ES2316559T3 (es) 2001-04-18 2009-04-16 Euro-Celtique S.A. Compuestos espiroindeno y espiroindano.
DE60229224D1 (de) 2001-04-18 2008-11-20 Euro Celtique Sa Nociceptin-analoga
JP4401076B2 (ja) 2001-04-18 2010-01-20 ユーロ−セルティーク エス．エイ． ベンズイミダゾロン化合物
YU82403A (sh) 2001-04-18 2006-08-17 Euroceltique S.A. Jedinjenja spiropirazola
WO2002088087A1 (fr) * 2001-04-26 2002-11-07 Takeda Chemical Industries, Ltd. Nouveaux derives heterocycliques
DE10123163A1 (de) * 2001-05-09 2003-01-16 Gruenenthal Gmbh Substituierte Cyclohexan-1,4-diaminderivate
EP1396488A1 (en) * 2001-05-23 2004-03-10 Mitsubishi Pharma Corporation Fused heterocyclic compound and medicinal use thereof
PE20030719A1 (es) * 2001-11-07 2003-08-28 Schering Corp Derivados de 8-[bis(2-halofenil)metil]-3-heteroaril-8-azabiciclo[3.2.1] octan-3-ol como agonistas del receptor de nociceptina orl-1
WO2003062234A1 (fr) 2002-01-23 2003-07-31 Yamanouchi Pharmaceutical Co., Ltd. Composes de quinoxaline
US7026312B2 (en) * 2002-03-14 2006-04-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
PT1491212E (pt) * 2002-03-29 2012-11-16 Mitsubishi Tanabe Pharma Corp Medicamento para distúrbios de sono
US20110092704A1 (en) 2002-10-17 2011-04-21 Parvis Gharagozloo Preparation of triazospiro compounds
DE10343098A1 (de) 2003-09-18 2005-04-14 Bayer Healthcare Ag Tetrahydrochinoxaline und ihre Verwendung
AR045939A1 (es) 2003-09-25 2005-11-16 Solvay Pharm Bv Derivados de bencimidazolona y quinazolinona como agonistas de los receptores orl 1 humanos
WO2005060947A2 (en) * 2003-12-19 2005-07-07 Sri International Agonist and antagonist ligands of the nociceptin receptor
DE10360793A1 (de) * 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
JP2007520493A (ja) 2004-02-03 2007-07-26 ユーロ−セルティーク エス．エイ． シアノイミノベンゾイミダゾールの合成
DE102004023332A1 (de) 2004-05-12 2006-01-19 Bayer Cropscience Gmbh Chinoxalin-2-on-derivate, diese enthaltende nutzpflanzenschützende Mittel und Verfahren zu ihrer Herstellung und deren Verwendung
EP1676843A1 (en) * 2004-12-31 2006-07-05 Nikem Research S.R.L. Substituted indole ligands for the ORL-1 receptor
JP2008543827A (ja) * 2005-06-17 2008-12-04 ファイザー株式会社 ＯＲＬ１受容体拮抗薬としてのα−（アリール−またはヘテロアリール−メチル）−βピペリジノプロパンアミド化合物
US7300947B2 (en) * 2005-07-13 2007-11-27 Banyu Pharmaceutical Co., Ltd. N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives
PE20071159A1 (es) * 2005-10-31 2007-11-30 Schering Corp Derivados de tropano 3-monosustituido como ligandos de receptores de nociceptina
TW200815405A (en) 2006-06-09 2008-04-01 Astrazeneca Ab Novel compounds
EP1873150A1 (en) 2006-06-30 2008-01-02 Nikem Research S.R.L. Fluorinated indoleamides useful as ligands of the ORL-1 receptor
KR101227072B1 (ko) * 2007-01-16 2013-01-29 시오노기세이야쿠가부시키가이샤 Ｏｒｌ-1 리간드로서의 헤테로시클릭-치환 피페리딘
CA2679530C (en) * 2007-03-01 2012-09-25 Mitsubishi Tanabe Pharma Corporation Benzimidazole compound and pharmaceutical use thereof
MX2010002449A (es) 2007-08-31 2010-09-07 Purdue Pharma Lp Compuestos de piperidina tipo quinoxalina sustituida y uso de los mismsos.
EP2324036B1 (en) * 2008-07-16 2014-12-03 Merck Sharp & Dohme Corp. Bicyclic heterocycle derivatives and methods of use thereof
WO2010010458A1 (en) 2008-07-21 2010-01-28 Purdue Pharma L.P. Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof

Also Published As

Publication number Publication date
US8476271B2 (en) 2013-07-02
DK2324013T3 (da) 2012-11-19
CL2011000148A1 (es) 2011-09-02
AU2009275218B2 (en) 2012-11-08
PL2324013T3 (pl) 2013-05-31
SI2324013T1 (sl) 2012-12-31
US10519156B2 (en) 2019-12-31
BRPI0911031B8 (pt) 2021-05-25
CN102105465B (zh) 2015-03-11
EP2324013A1 (en) 2011-05-25
SG192539A1 (en) 2013-08-30
DK2324013T6 (en) 2014-12-15
BRPI0911031B1 (pt) 2021-05-11
CA2730288C (en) 2016-09-13
JP2011528707A (ja) 2011-11-24
US9890164B2 (en) 2018-02-13
AU2009275218A1 (en) 2010-01-28
MY153948A (en) 2015-04-15
US11111246B2 (en) 2021-09-07
UA99540C2 (ru) 2012-08-27
EP2324013B3 (en) 2014-10-22
IL210549A (en) 2017-09-28
RU2500678C2 (ru) 2013-12-10
TW201016697A (en) 2010-05-01
WO2010010458A1 (en) 2010-01-28
US20110178090A1 (en) 2011-07-21
ES2393849T3 (es) 2012-12-28
US20200223847A1 (en) 2020-07-16
US20160009717A1 (en) 2016-01-14
PE20140102A1 (es) 2014-02-06
NZ590416A (en) 2012-10-26
PT2324013E (pt) 2012-12-24
JP5416210B2 (ja) 2014-02-12
KR20110031993A (ko) 2011-03-29
US20180370971A1 (en) 2018-12-27
AU2009275218C1 (en) 2015-02-05
RU2011106375A (ru) 2012-08-27
US9145408B2 (en) 2015-09-29
TW201329077A (zh) 2013-07-16
IL210549A0 (en) 2011-03-31
EP2537844A1 (en) 2012-12-26
BRPI0911031A2 (pt) 2017-01-17
US20130274265A1 (en) 2013-10-17
HK1157763A1 (en) 2012-07-06
ZA201100189B (en) 2011-09-28
PL2324013T6 (pl) 2015-11-30
US20180148449A1 (en) 2018-05-31
MX2011000872A (es) 2011-07-29
ES2393849T7 (es) 2015-01-28
SMT201200053B (it) 2013-01-14
HRP20120841T4 (hr) 2015-07-03
CO6341627A2 (es) 2011-11-21
KR101333660B1 (ko) 2013-11-27
CA2730288A1 (en) 2010-01-28
TWI432434B (zh) 2014-04-01
CY1113485T1 (el) 2016-06-22
RS52590B2 (sr) 2018-05-31
HRP20120841T1 (hr) 2012-11-30
CN102105465A (zh) 2011-06-22
RS52590B (en) 2013-04-30
IL254218A0 (en) 2017-10-31
PE20110416A1 (es) 2011-06-22
EP2324013B1 (en) 2012-09-19

Similar Documents

Publication Publication Date Title
AR072578A1 (es) Compuestos de piperidina puenteada tipo quinoxalina sustituida y los usos de los mismos
UY31050A1 (es) Antagonistas de trpv1 y usos de los mismos
CL2009000498A1 (es) Compuestos derivados de benzo [f][1,7]naftiridin sustituidos, moduladores de receptor toll; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedad infecciosa, inflamatoria, dermatologica, respiratoria o inmune.
ECSP099780A (es) Nuevos inhibidores macrociclicos de la replicacion del virus de hepatitis c
AR106652A1 (es) Compuestos para tratar la esclerosis lateral amiotrófica
AR081058A1 (es) Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer.
PE20151951A1 (es) Heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis de infeccion por el virus de la hepatitis b
AR095192A1 (es) Quinolina y quinazolinamidas como modulares de canales de sodio
ECSP099792A (es) Nuevos peptidos inhibidores de la replicacion del virus de hepatitis c
CL2012000999A1 (es) Compuestos derivados de pirazoloespirocetona sustituida, inhibidores de acetil-coa carboxilasa; composicion farmaceutica que los comprende; uso para tratar o retrasar la progresion o el inicio de diabetes tipo 2, higado graso no alcoholico (hgna) o la resistencia hepatica a la insulina.
UY33961A (es) Compuestos de bis(fuoroalquil)-1,4-benziodiazepinona
AR078153A1 (es) Compuestos y composiciones como moduladores de la actividad de tlr
PA8596001A1 (es) Inhibidores de la arn polimerasa dependiente de arn del virus de la hepatitis c y composiciones y tratamientos que los usan
CU20090209A7 (es) Compuestos macrocíclicos como inhibidores de la replicación viral
PE20081894A1 (es) Derivados de isoindolina 4&#39;-o-sustituidos y composiciones que los comprenden y metodos para usarlos
ECSP066570A (es) Ácidos carboxílicos macrocíclicos y acilsulfonamidas como inhibidores de replicación del hcv
ECSP10010612A (es) Nuevos inhibidores macrociclicos de la replicacion del virus de la hepatitis c
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
UY29266A1 (es) Compuestos de piridazinona
AR083879A1 (es) Analogos de aminoglicosidos antibacterianos, metodos de preparacion y uso como agentes terapeuticos
DOP2017000188A (es) Compuestos de benzoxaborol 4-sustituidos y uso de los mismos
AR074353A1 (es) Acidos naftalen-2-il-aceticos sustituidos, composiciones farmaceuticas que los contienen, y uso de los mismos en el tratamiento de enfermedades alergicas,tales como rinitis, asma y dermatititis atopica.
UY30787A1 (es) &#34;inhibidores benzoimidazolicos de trpv1&#34;
AR054707A1 (es) Derivados de octahidropirrolo 3,4-c pirrol, un procedimiento para su preparacion, una composicion farmaceutica y uso del compuesto para la fabricacion de un medicamento
CL2010001566A1 (es) Compuesto derivado de piperidinilo, modulador de la actividad de los receptores de la quimiocina; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades inflamatorias, alergicas, autoinmune.

Legal Events

Date Code Title Description
FG Grant, registration